POLYCHEMOTHERAPY INDUCED CARDIOMYOPATHY IN PATIENT WITH BREAST CANCER
https://doi.org/10.17650/1818-8338-2011-3-109-111
Abstract
Clinical observation of the patient with dilated cardiomyopathy, developed after chemotherapy for breast cancer.
About the Authors
O. N. Korneeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
O. M. Drapkina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. V. Kozlova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
2. Smith I., Procter M., Gelber R.D., et al.; HERA study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
3. Miolo G.M., Mura N.L., Nigri P., et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol 2006;40(3):149–61.
Review
For citations:
Korneeva O.N., Drapkina O.M., Kozlova E.V., Ivashkin V.T. POLYCHEMOTHERAPY INDUCED CARDIOMYOPATHY IN PATIENT WITH BREAST CANCER. The Clinician. 2011;5(3):109-111. (In Russ.) https://doi.org/10.17650/1818-8338-2011-3-109-111
Views:
1189
Email this article 